Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 733

1.

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Sutter G, Staib C.

Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71. Review.

PMID:
14529359
2.

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

Rimmelzwaan GF, Sutter G.

Expert Rev Vaccines. 2009 Apr;8(4):447-54. doi: 10.1586/erv.09.4. Review.

PMID:
19348560
3.
4.

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.

Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M.

Virus Res. 2006 Mar;116(1-2):11-20. Epub 2005 Oct 7.

PMID:
16214252
5.

Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.

Taylor J, Paoletti E.

Prog Vet Microbiol Immunol. 1988;4:197-217. Review.

PMID:
3078866
6.
7.

Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.

Volz A, Sutter G.

Adv Virus Res. 2017;97:187-243. doi: 10.1016/bs.aivir.2016.07.001. Epub 2016 Aug 1. Review.

PMID:
28057259
8.

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

Drexler I, Staib C, Sutter G.

Curr Opin Biotechnol. 2004 Dec;15(6):506-12. Review.

PMID:
15560976
9.

Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.

Ober BT, Brühl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, Savidis-Dacho H, Gerencer M, Falkner FG.

J Virol. 2002 Aug;76(15):7713-23.

10.

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.

Moorthy VS, Pinder M, Reece WH, Watkins K, Atabani S, Hannan C, Bojang K, McAdam KP, Schneider J, Gilbert S, Hill AV.

J Infect Dis. 2003 Oct 15;188(8):1239-44. Epub 2003 Sep 30.

PMID:
14551895
11.

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.

Moorthy VS, McConkey S, Roberts M, Gothard P, Arulanantham N, Degano P, Schneider J, Hannan C, Roy M, Gilbert SC, Peto TE, Hill AV.

Vaccine. 2003 May 16;21(17-18):1995-2002.

PMID:
12706689
12.

MVA as a vector for vaccines against HIV-1.

Im EJ, Hanke T.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S89-97. Review.

PMID:
15285708
13.

Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.

Weyer J, Rupprecht CE, Mans J, Viljoen GJ, Nel LH.

Vaccine. 2007 May 22;25(21):4213-22. Epub 2007 Mar 22.

PMID:
17434244
14.

Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A.

Viruses. 2014 Jul 17;6(7):2735-61. doi: 10.3390/v6072735. Review.

15.

A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.

Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, Robson KJ, Hill AV.

Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):290-5. Epub 2003 Dec 23.

16.

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.

McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV.

Nat Med. 2003 Jun;9(6):729-35. Epub 2003 May 25.

PMID:
12766765
17.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

18.

Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.

Verheust C, Goossens M, Pauwels K, Breyer D.

Vaccine. 2012 Mar 30;30(16):2623-32. doi: 10.1016/j.vaccine.2012.02.016. Epub 2012 Feb 17. Review.

19.

Construction and isolation of recombinant MVA.

Staib C, Drexler I, Sutter G.

Methods Mol Biol. 2004;269:77-100. Review.

PMID:
15114009

Supplemental Content

Support Center